Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai Delivers Positive H1 Earnings on Innovative Drugs, Export Growth
Chugai Pharmaceutical posted higher revenue and profit for the first half of 2025, fueled by strong sales of new products and steady exports to Roche, offsetting drug price cuts and generic erosion in Japan. For the six months through June,…
To read the full story
Related Article
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
- Chugai Drops Five Early-Stage Programs to Refocus Pipeline
July 25, 2025
- Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
- Chugai Net Profit Jumps to Nearly 300 Billion Yen on Brisk Exports
October 28, 2024
- Chugai’s H1 Profit Marks 2-Digit Growth on Export to Roche Despite Lower Sales
July 26, 2024
- Chugai’s Q1 Sales Drop 24% on End of Ronapreve Govt Purchase and Generic Competition
April 25, 2024
- Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
February 2, 2024
- Chugai Marks 2-Digit Growth in Core Earnings in H1 on Robust Sales, Exports
July 28, 2023
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…